AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
暂无分享,去创建一个
Ying Lu | Ka-Loh Li | Roland G Henry | Savannah C Partridge | Robert C Brasch | N. Hylton | R. Henry | Donghui Wang | S. Partridge | J. Gibbs | Ying Lu | R. Brasch | John W. Park | T. McShane | M. Pallavicini | L. Wilmes | Ka-Loh Li | D. Hu-Lowe | D. Shalinsky | John W Park | Jessica Gibbs | Lisa J Wilmes | Nola M Hylton | Donghui Wang | David R Shalinsky | Maria G Pallavicini | Teresa M McShane | Lisa M Fleming | Dana Hu-Lowe | L. M. Fleming
[1] G Brix,et al. Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.
[2] R. Herbst,et al. Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors , 2004 .
[3] Ulrik B Nielsen,et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] M. Ogan,et al. Albumin labeled with Gd-DTPA: an intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. , 1987, Investigative radiology.
[5] Gavin Thurston,et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. , 2004, The American journal of pathology.
[6] A. Padhani,et al. Assessing changes in tumour vascular function using dynamic contrast‐enhanced magnetic resonance imaging , 2002, NMR in biomedicine.
[7] Laura Esserman,et al. Contrast‐Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma , 1999, The breast journal.
[8] Hadassa Degani,et al. Parametric imaging of tumor perfusion using flow‐ and permeability‐limited tracers , 2002, Journal of magnetic resonance imaging : JMRI.
[9] Andrea Sbarbati,et al. In Vivo Assessment of Antiangiogenic Activity of SU6668 in an Experimental Colon Carcinoma Model , 2004, Clinical Cancer Research.
[10] C S Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[11] N. Ferrara. Vascular endothelial growth factor as a target for anticancer therapy. , 2004, The oncologist.
[12] N. van Bruggen,et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. , 1998, Cancer investigation.
[13] T. Helbich,et al. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS‐325) with correlations to histopathology , 2001, Journal of magnetic resonance imaging : JMRI.
[14] I. Zuna,et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution , 2002, European Radiology.
[15] A. Padhani. MRI for assessing antivascular cancer treatments. , 2003, The British journal of radiology.
[16] L. Esserman,et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. , 2005, AJR. American journal of roentgenology.
[17] R. Edelman,et al. Magnetic resonance imaging (2) , 1993, The New England journal of medicine.
[18] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[19] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[20] Stanley J. Wiegand,et al. Vascular-specific growth factors and blood vessel formation , 2000, Nature.
[21] P M Carpenter,et al. Characterization of N‐ethyl‐N‐nitrosourea‐induced malignant and benign breast tumors in rats by using three MR contrast agents , 1999, Journal of magnetic resonance imaging : JMRI.
[22] G Brix,et al. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. , 1994, Magnetic resonance imaging clinics of North America.
[23] W E Reddick,et al. MR imaging of tumor microcirculation: Promise for the new millenium , 1999, Journal of magnetic resonance imaging : JMRI.
[24] J. Hennig,et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. , 2002, Cancer research.
[25] O Nalcioglu,et al. Investigation of longitudinal vascular changes in control and chemotherapy‐treated tumors to serve as therapeutic efficacy predictors , 1999, Journal of magnetic resonance imaging : JMRI.
[26] D. Hanahan,et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.
[27] J. Folkman. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. , 1990, Cancer metastasis reviews.
[28] D. Marmé. The impact of anti-angiogenic agents on cancer therapy , 2003, Journal of Cancer Research and Clinical Oncology.
[29] P. Tofts,et al. Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.